E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, ...

today announced that it has dosed its first patient in a Phase 2 clinical trial of Modified Atrial Natriuretic Peptide (MANP) for the treatment of Resistant Hypertension (BOLD-HTN). MANP was ...

Obesity influences the thresholds, but even in nonobese patients with dyspnea, optimal cutoffs may be lower than recommended.

Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...

Congenital heart disease or defect is a common type of birth defect that needs medical attention. The exact cause is unclear, ...

Clinical worsening events are defined as all-cause death, non-planned PAH worsening-related hospitalization of ≥ 24 hours, atrial septostomy ... or achievement of N-terminal pro-B-type natriuretic ...

P-wave terminal force in ECG lead V1 (PTFV1) and left atrial dimension index (LADI) were modeled as continuous variables, whereas N-terminal pro-B-type natriuretic peptide (NT-proBNP) was ...

Background and aims N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a well-established biomarker in clinical practice, particularly for heart failure, but its role in predicting atrial ...

Previous studies on the value of brain natriuretic peptide in diastolic dysfunction have been largely limited to male subjects. The authors found that female gender, in addition to diastolic ...

Background Iron deficiency (ID) is common in patients with atrial fibrillation/flutter (AF), but its prognostic implications and optimal diagnostic criteria, particularly in those with and without ...

Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.